Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention in this population.

Inclusion Criteria:

• Active diagnosis of primary invasive non-metastatic breast cancer, stages I-III
• Female
• 18 to 85 years of age
• Scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane)
• Absence of contraindications to exercise
• Study clinician approval
• Able to give consent
• Informed consent obtained from the subject and documentation of subject agreement to comply with study-related process

Exclusion Criteria:

• Do not meet inclusion criteria
• Receiving targeted therapies (CDK4/6 or PARP inhibitors)
• Receiving radiation therapy concurrent with chemotherapy
• Lymphedema stage ≥ 2 prior to study enrollment
• Any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
• Current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

Women who will receive chemotherapy for breast cancer